EGFR and non-small cell lung carcinoma: Furthermore, the National Medical Products Administration (NMPA) of China has approved additional EGFR-TKIs, including icotinib, almonertinib, and furmonertinib, for the treatment of EGFR-mutant NSCLC (16).